Department of Neurology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Neuroscience Centre, Samsung Medical Centre, Seoul, Republic of Korea.
PLoS One. 2021 Oct 21;16(10):e0258897. doi: 10.1371/journal.pone.0258897. eCollection 2021.
The composite autonomic symptom scale-31 (COMPASS-31) is a self-rated questionnaire that evaluates diverse autonomic symptoms. In the present study, we developed the Korean version of the COMPASS-31 (K-COMPASS-31) with appropriate translation, and verified its reliability and internal and external validity in patients with Parkinson's disease (PD).
The original COMPASS-31 was translated independently into Korean by two bilingual neurologists. Test-retest reliability was evaluated at a 2-week interval. We investigated the correlations between the K-COMPASS-31, the scale for outcomes in PD-autonomic (SCOPA-AUT), and the results of an autonomic function test (AFT), respectively.
A total of 90 patients with PD (47 females; mean age, 63.4 ± 10.8 years) were enrolled. The K-COMPASS-31 showed excellent test-retest reliability (intra-class correlation coefficient = 0.874, p < 0.001) and internal validity (Cronbach's α-coefficient = 0.878). The COMPASS-31 was positively correlated with SCOPA-AUT (r = 0.609, p < 0.001) and the results of the AFT.
In conclusion, the K-COMPASS-31 showed excellent reliability and validity for the assessment of autonomic symptoms in PD patients. The K-COMPASS-31 is an easy-to-repeat and widely used tool for investigating autonomic dysfunction in various neurologic disorders and enables comparison of autonomic dysfunction among neurologic disorders. We recommend the K-COMPASS-31 as a valid instrument for use in clinical practice for patients with PD.
复合自主症状量表-31(COMPASS-31)是一种自评问卷,用于评估多种自主症状。本研究通过适当的翻译,开发了 COMPASS-31 的韩文版(K-COMPASS-31),并在帕金森病(PD)患者中验证了其信度、内部和外部效度。
由两名双语神经科医生独立将原始 COMPASS-31 翻译为韩文。在 2 周的间隔内评估测试-重测信度。我们分别研究了 K-COMPASS-31 与帕金森病自主症状量表(SCOPA-AUT)和自主功能测试(AFT)结果之间的相关性。
共纳入 90 例 PD 患者(女性 47 例;平均年龄 63.4±10.8 岁)。K-COMPASS-31 具有极好的测试-重测信度(组内相关系数=0.874,p<0.001)和内部有效性(Cronbach's α 系数=0.878)。COMPASS-31 与 SCOPA-AUT(r=0.609,p<0.001)和 AFT 结果呈正相关。
总之,K-COMPASS-31 对 PD 患者自主症状的评估具有极好的信度和效度。K-COMPASS-31 是一种易于重复且广泛用于研究各种神经疾病自主功能障碍的工具,可用于比较不同神经疾病之间的自主功能障碍。我们建议将 K-COMPASS-31 作为 PD 患者临床实践中有效的工具。